Kidney Res Clin Pract 2019 Sep; 38(3): 257-259
To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
Dong Ho Shin
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
Correspondence to: Dong Ho Shin
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul 05355, Korea. E-mail:

Edited by Gheun-Ho Kim, Hanyang University, Seoul, Korea
Received: July 11, 2019; Revised: July 17, 2019; Accepted: July 17, 2019; Published online: September 30, 2019.
© The Korean Society of Nephrology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although there is no universally accepted definition of hyperuricemia, serum urate level of > 7.0 mg/dL, based on the limit of urate solubility in body fluid, is widely accepted as the reference for hyperuricemia [1]. Meanwhile, asymptomatic hyperuricemia is defined as elevated serum urate levels in the absence of signs and symptoms of monosodium urate crystal deposition disease. Asymptomatic hyperuricemia is frequently associated with other disorders such as hypertension, chronic kidney disease (CKD), cardiovascular disease, and insulin resistance [2]. To prevent gouty arthritis, cardiovascular disease, and renal failure, the Japanese guidelines for management of hyperuricemia and gout recommends initiating pharmacologic urate-lowering therapy for asymptomatic hyperuricemia when serum urate levels increase to > 8.0 mg/dL [3]. However, this approach is not recommended in the United States and Europe, because inappropriate administration of such therapy for asymptomatic hyperuricemia has been reported to be associated with considerable risks of life-threatening skin and systemic side effects [2].

The kidneys play an important role in uric acid excretion through a complex process involving filtration, reabsorption, and tubular secretion [4]. Generally, decreased kidney function leads to hyperuricemia due to decreased excretion of uric acid. However, there is accumulating evidence that hyperuricemia has a causal relationship with the deterioration of kidney function [5,6], although this relationship remains a matter of some debate. However, a survey concerning the management of asymptomatic hyperuricemia in patients with CKD by Japanese nephrologists showed that most nephrologists (84–89%) treated asymptomatic hyperuricemia in patients with CKD stage 3 to 5 in order to prevent CKD progression or cardiovascular events [7]. In the current issue of Kidney Research and Clinical Practice, Cha et al [8] report the results of a survey of Korean nephrologists’ perceptions regarding the diagnosis and management of asymptomatic hyperuricemia in patients with CKD. In this study, most respondents (80.4%) reported that they do treat asymptomatic hyperuricemia in patients with CKD, in line with the results from the Japanese survey. In particular, there were overall fewer respondents in the Korean study compared with those in the Japanese study (12.6% vs. 40%). Based on the results of the former survey, the authors carefully suggest that the definition of hyperuricemia should be serum uric acid levels of > 7.0 mg/dL, irrespective of CKD stage. In addition, they recommend that pharmacologic urate-lowering therapy should be considered for patients with serum uric levels of > 8.0 mg/dL. However, further well-designed and well-conducted studies are required to obtain definitive conclusions on the efficacy of urate-lowering agents for the treatment of asymptomatic hyperuricemia in patients with CKD. As summarized in Table 1 [5,6,9], three recent clinical studies have investigated this issue. First, the febuxostat vs. placebo randomized controlled trial (RCT) regarding reduced renal function in patients with hyperuricemia complicated by CKD stage 3 (FEATHER) study—an RCT—aimed to assess the effects of urate-lowering agents on the kidney function and to determine whether febuxostat attenuates the deterioration of the kidney function of patients with CKD and asymptomatic hyperuricemia [9]. The subgroup analysis of the FEATHER study demonstrated a significant benefit in terms of preserved kidney function following febuxostat administration in patients without proteinuria or with serum creatinine levels below the median. However, there was no significant difference in estimated glomerular filtration rate (eGFR) decline between the febuxostat and placebo groups. Second, the febuxostat for cerebral and cardiorenovascluar events prevention study (FREED) also an RCT that evaluated the effects of febuxostat in patients ≥ 65 years of age with hyperuricemia who were at risk of any cerebral or cardiovascular disease [5]. Preliminary results revealed that reduced serum uric acid levels in response to febuxostat have a protective effect on kidney function. In this study, however, kidney failure was defined as a composite outcome, including the occurrence of proteinuria as well as increased serum creatinine levels. Third, a retrospective epidemiologic cohort study conducted over 8 years to determine whether the administration of urate-lowering agents was beneficial for patients with mild-to-moderate CKD. The study, by Levy et al [6], suggested that urate-lowering therapy was not associated with any improvement in eGFR in patients with CKD stage 4. Thus, it cannot be concluded that pharmacologic urate-lowering agents have a protective effect on kidney function in patients with CKD and asymptomatic hyperuricemia.

The choice of xanthine oxidase inhibitor as the first-line urate-lowering agent is another controversial issue. Allopurinol has been commonly used for over 50 years. However, adverse effects including rash, leukopenia or thrombocytopenia, and diarrhea have been reported in 3% to 5% of patients. Furthermore, allopurinol-hypersensitivity syndrome (AHS) is a life-threatening side effect, with a mortality rate of 20% to 25%. In particular, concurrent thiazide use and kidney failure are associated with increase in the risk of AHS. Moreover, the association of human leukocyte antigen-B*5801 with AHS has been demonstrated, and the prevalence of this phenotype is relatively high (12.2%) in the Korean population [10]. On the other hand, febuxostat is well tolerated in patients who are hypersensitive or intolerant to allopurinol [10,11]. Febuxostat is metabolized predominantly in the liver, with only 1% to 6% of the dosage being excreted through the kidneys [12], enabling safe administration in patients with CKD. However, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES) trial revealed that all-cause and cardiovascular mortality rates were higher among patients using febuxostat than among those using allopurinol [13]. Because there were no preclinical cardiovascular studies demonstrating the toxic effects of febuxostat in terms of cardiac rhythm, function, or metabolism, the investigators concluded that clarifying the mechanism underling this risk of death is difficult.

Considering the side effects of urate-lowering agents in patients with CKD and the lack of clinical trials showing protective effect of these drugs on kidney function in patients with CKD and asymptomatic hyperuricemia, it is premature to recommend this therapy for asymptomatic hyperuricemia in patients with CKD. Conclusive evidence that pharmacologic urate-lowering therapy attenuates CKD progression in patients with less kidney damage and asymptomatic hyperuricemia is required before firm clinical guidelines can be decided upon.

Conflicts of interest

The author has no conflicts of interest to declare.


Summary of clinical studies investing the effects of urate-lowering agents on kidney function

Reference Study design and duration Urate-lowering therapy Inclusion criteria Number of patients Renal outcomes
Kimura et al [9] Placebo-controlled randomized double-blind parallel-group study Febuxostat 10 mg to 40 mg vs. placebo Age ≥ 20 years 443 No significant slope difference in eGFR between groups
Serum urate level > 7 mg/dL
No history of gout
Duration: 108 weeks eGFR 30 to 59 mL/min/1.73 m2
Kojima et al [5] Randomized open parallel controlled study Febuxostat 10 mg to 40 mg vs. allopurinol 100 mg Age ≥ 65 years 1,070 Febuxostat prevented renal failurea
Serum urate level > 7 mg/dL
Duration: 3 years Hypertension and/or type 2 diabetes and/or cerebrocardiovascular disease and/or eGFR 30 to 59 mL/min/1.73 m2
Levy et al [6] Retrospective epidemiologic study Allopurinol, febuxostat, or probenecid vs. no urate-lowering therapy Age ≥ 18 years 12,751 Patients with eGFR 30 to 89 mL/min/1.73 m2 in receiving urate-owering therapy had 30% improvement in eGFR
Serum urate level > 7 mg/dL
Duration: > 8 years eGFR 15 to 89 mL/min/1.73 m2

eGFR, estimated glomerular filtration rate.

Renal failure was defined as development of microalbuminuria, progression to overt proteinuria, worsening of overt proteinuria, doubling of serum creatinine level, or progression to end-stage renal disease.
  1. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-38.
    Pubmed CrossRef
  2. Chalès G. How should we manage asymptomatic hyperuricemia?. Joint Bone Spine 2019;86:437-443.
    Pubmed CrossRef
  3. Yamanaka H, Metabolism TG. Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J 2012;55:324-329.
  4. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 2012;19:358-371.
    Pubmed KoreaMed CrossRef
  5. Kojima S, Matsui K, Ogawa H, et al, Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol 2017;69:169-175.
    Pubmed CrossRef
  6. Levy G, Shi JM, Cheetham TC, Rashid N. Urate-lowering therapy in moderate to severe chronic kidney disease. Perm J 2018;22:17-142.
    Pubmed KoreaMed
  7. Nakaya I, Namikoshi T, Tsuruta Y, et al, School of Designing Clinical Study for Nephrologists and Dialysis Physicians. Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. Nephrology (Carlton) 2011;16:518-521.
    Pubmed CrossRef
  8. Cha RH, Kim SH, Bae EH, et al. Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: a questionnaire survey. Kidney Res Clin Pract 2019;38:373-381.
    Pubmed CrossRef
  9. Kimura K, Hosoya T, Uchida S, et al, FEATHER Study Investigators. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 2018;72:798-810.
    Pubmed CrossRef
  10. Khanna D, Fitzgerald JD, Khanna PP, et al, American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-1446.
    Pubmed KoreaMed CrossRef
  11. Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008;4:1209-1220.
    Pubmed KoreaMed CrossRef
  12. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-841.
    Pubmed CrossRef
  13. White WB, Saag KG, Becker MA, et al, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200-1210.
    Pubmed CrossRef


This Article


Indexed/Covered by